Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
Related Experiment Video
Updated: May 31, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Farah Babakhani1, Abraham Gomez, Nikki Robert
1Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Rd., Suite C, San Diego, CA 92121, USA. fbabakhani@optimerpharma.com
Abstract:
Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).
Related Concept Videos
Microbiota Modulation by Antibiotics
Inhibitors of Bacterial DNA Synthesis
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Clinical Significance of Antibiotic Resistance
Antimicrobial Effectiveness
Inhibitors of Bacterial Protein Synthesis
